Nature Communications

The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2026-08-07

Full text

DOI https://doi.org/10.1038/s41467-026-76313-w